Drug DevelopmentCadrenal received orphan drug designation for Tecarfarin, underscoring the potential for a new treatment option in the anticoagulant market.
Financial PerformanceCadrenal's recent financial results showed an EPS that exceeded expectations, signaling stronger financial health and potentially increasing investor confidence.
Regulatory MilestoneAnalyst confidence is growing in Cadrenal's prospects for FDA approval to include TTR as a key measure in clinical trials, which could be a significant step forward for the company.